With its innovative fusion cancer vaccine that greatly enhances the target specificity of T cells, Tokyo-based CyTIX is poised to take advantage of the biopharma industry’s increasing interest ...

RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for ...